secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2026-03-11T23:59:59+00:00
Accession:  0001104659-26-026407
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Therapeutics sells 5.7M shares for $20M gross proceeds in ATM offering
------------------------------------------------------------------------------

- 5.7M shares sold on March 10, 2026 for aggregate gross proceeds of $20.0M.
- Purchasers include Frazier Life Sciences, Kalehua Capital, and Adage Capital Partners LP.
- Sale under amended sales agreement with Leerink Partners and Cantor Fitzgerald dated Feb 27, 2025.
- Gross proceeds of $20M implies average price per share of approximately $3.51.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926026407/0001104659-26-026407-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926026407/acrs-20260310x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-026407

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer